Bernard Gilly
Founder en PIXIUM VISION .
Perfil
Bernard Jacques Alex Gilly is the founder of Domain Therapeutics SA (founded in 2001), Fovea Pharmaceuticals SA (founded in 2005), Pixium Vision SA (founded in 2011), Gensight Biologics SA (founded in 2012), Tissium SA (founded in 2013), Prophesee SA (founded in 2014), iBionext SAS (founded in 2015), and Grai Matter Labs SAS (founded in 2016).
He is also the founder of Sequoia Pharmaceuticals, Inc., Cellzome AG, CareX SA, and Tilak Healthcare SAS.
Dr. Gilly's current job(s) include Chairman & Chief Executive Officer at Brainever SAS, Independent Chairman at Eye Tech Care SA, Chairman & President at Chronolife SAS, Director at PX Therapeutics SA, and Director at T-Heart SAS.
Dr. Gilly's former job(s) include President & Chief Executive Officer at Transgene SA (1992-2000), Chairman & Chief Executive Officer at Kutexis, Director at Wavecom SA (2009), Director at KALA BIO, Inc., Non-Executive Director at Enterome SA, Director at Mnemosyne, Vice President-Research & Development at bioMérieux SA, Partner at Sofinnova Partners SAS (2000-2005), Executive Vice President-Ophthalmology Division at Sanofi Pasteur, Vice President-Research & Development at Pasteur Mérieux Connaught, and President at Passage De L'Innovation.
Dr. Gilly's education history includes a doctorate from the University of Rhode Island, an MBA from INSEAD, a doctorate from the University of Rennes, and an undergraduate degree from Ecole Nationale Supérieure Agronomique.
Dr. Gilly is also the founder of Sequoia Pharmaceuticals, Inc., Cellzome AG, CareX SA, and Tilak Healthcare SAS.
Cargos activos de Bernard Gilly
| Empresas | Cargo | Inicio |
|---|---|---|
| PIXIUM VISION | Founder | 28/12/2011 |
T-Heart SAS
 T-Heart SAS Miscellaneous Commercial ServicesCommercial Services T-Heart SAS is an investment holding company with interest in research and development services on natural sciences sector. The company was founded on December 06, 2018 and is headquartered in Paris, France. | Director/Board Member | - |
Grai Matter Labs SAS
 Grai Matter Labs SAS Information Technology ServicesTechnology Services Grai Matter Labs SAS provides computer programming services. The company was founded on May 9, 2016 and is headquartered in Paris, France. | Founder | 01/01/2016 |
Brainever SAS
 Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Chief Executive Officer | - |
Tilak Healthcare SAS
 Tilak Healthcare SAS Information Technology ServicesTechnology Services Tilak Healthcare SAS develops platform of serious medical games. It enables diagnostic and therapy of ophthalmologic diseases through early detection and self-tracking. The company was founded in 2016 and is headquartered in Paris, France. | Founder | - |
Chronolife SAS
 Chronolife SAS Miscellaneous Commercial ServicesCommercial Services Chronolife SAS engages in the research and development activity in natural sciences. The company is headquartered in Paris, France. | Chairman | - |
iBionext SAS
 iBionext SAS Investment ManagersFinance iBionext SAS (iBionext) is an independent venture capital firm headquartered in Paris, France. The firm was founded in 2012 by Christophe Bancel and Alexia Perouse. | Founder | 17/09/2015 |
PX Therapeutics SA
 PX Therapeutics SA Miscellaneous Commercial ServicesCommercial Services PX Therapeutics SA manufactures and develops recombinant proteins and monoclonal antibodies. Its services include protein engineering, optimization of drug candidates, humanization of antibodies, and production and release of GMP batches for clinical studies. The firm specializes in the field of in-vivo and in-vitro diagnostics, industrial enzymes, and ancillary products. The company was founded by Tristan Rousselle and Nicolas Mouz in November 2000 and is headquartered in Grenoble, France. | Director/Board Member | - |
Prophesee SA
 Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | Founder | 01/01/2014 |
| ░░░ ░░░░ ░░░░ ░░ | ░░░░░░░░ | - |
Antiguos cargos conocidos de Bernard Gilly.
| Empresas | Cargo | Fin |
|---|---|---|
| ░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formación de Bernard Gilly.
| University of Rhode Island | Doctorate Degree |
| INSEAD | Masters Business Admin |
| University of Rennes | Doctorate Degree |
| Ecole Nationale Supérieure Agronomique | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 5 |
|---|---|
| TRANSGENE | Health Technology |
| KALA BIO, INC. | Health Technology |
| BIOMÉRIEUX | Health Technology |
| PIXIUM VISION | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Empresas privadas | 23 |
|---|---|
Wavecom SA
 Wavecom SA Packaged SoftwareTechnology Services Wavecom SA provides embedded wireless technology solutions for machine-to-machine communication. The company offers a range of GSM/GPRS, CDMA, EDGE, and 3G Wireless CPUs as well as programmable processors. Its solutions are used in automotive telematics, smart metering, fleet management, GSM/GPS/satellite tracking, wireless alarms, WLL, remote monitoring, and other machine-to-machine applications. The firm was founded on June 28, and is headquartered in Issy-les-Moulineaux, France. | Technology Services |
Sequoia Pharmaceuticals, Inc.
 Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Health Technology |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |
Cellzome AG
 Cellzome AG Miscellaneous Commercial ServicesCommercial Services Cellzome AG provides drug discovery services. It is a research company with proprietary proteomics technology for target and lead identification and a drug discovery program in Alzheimer's disease. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Commercial Services |
CareX SA
 CareX SA Pharmaceuticals: MajorHealth Technology CareX SA is a privately held biopharmaceutical company located in Strasbourg, France, that is committed to the discovery and development of innovative, safe and effective medicines for the treatment of diseases linked to the metabolic syndrome. The company was founded in 2001 and is headquartered in Illkirch-Graffenstaden, France | Health Technology |
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Sanofi Pasteur
 Sanofi Pasteur BiotechnologyHealth Technology Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France. | Health Technology |
| Pasteur Mérieux Connaught | |
PX Therapeutics SA
PX Therapeutics SA Miscellaneous Commercial ServicesCommercial Services PX Therapeutics SA manufactures and develops recombinant proteins and monoclonal antibodies. Its services include protein engineering, optimization of drug candidates, humanization of antibodies, and production and release of GMP batches for clinical studies. The firm specializes in the field of in-vivo and in-vitro diagnostics, industrial enzymes, and ancillary products. The company was founded by Tristan Rousselle and Nicolas Mouz in November 2000 and is headquartered in Grenoble, France. | Commercial Services |
Eye Tech Care SA
 Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Health Technology |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
Tissium SA
 Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Health Technology |
| Mnemosyne | |
Prophesee SA
Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | Health Technology |
iBionext SAS
iBionext SAS Investment ManagersFinance iBionext SAS (iBionext) is an independent venture capital firm headquartered in Paris, France. The firm was founded in 2012 by Christophe Bancel and Alexia Perouse. | Finance |
Brainever SAS
Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Health Technology |
Chronolife SAS
Chronolife SAS Miscellaneous Commercial ServicesCommercial Services Chronolife SAS engages in the research and development activity in natural sciences. The company is headquartered in Paris, France. | Commercial Services |
Tilak Healthcare SAS
Tilak Healthcare SAS Information Technology ServicesTechnology Services Tilak Healthcare SAS develops platform of serious medical games. It enables diagnostic and therapy of ophthalmologic diseases through early detection and self-tracking. The company was founded in 2016 and is headquartered in Paris, France. | Technology Services |
Grai Matter Labs SAS
Grai Matter Labs SAS Information Technology ServicesTechnology Services Grai Matter Labs SAS provides computer programming services. The company was founded on May 9, 2016 and is headquartered in Paris, France. | Technology Services |
| Kutexis | Miscellaneous |
T-Heart SAS
T-Heart SAS Miscellaneous Commercial ServicesCommercial Services T-Heart SAS is an investment holding company with interest in research and development services on natural sciences sector. The company was founded on December 06, 2018 and is headquartered in Paris, France. | Commercial Services |
Passage De L'Innovation
 Passage De L'Innovation Real Estate DevelopmentFinance Passage De L'Innovation is a French company that engages in the rental of land and other real estate. The private company is based in Paris, France. | Finance |
- Bolsa de valores
- Insiders
- Bernard Gilly
